Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARAH ANN WEISS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1629356803
CMS profile
1391149
Location
NEW BRUNSWICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$539.72

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $269.86 1
Travel and Lodging $269.86 1

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $539.72 2

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARAH ANN WEISS

NPI 1629356803 · CMS profile ID 1391149

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

NEW BRUNSWICK, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1629356803?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARAH ANN WEISS, NPI 1629356803, CMS profile ID 1391149. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1629356803?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SARAH ANN WEISS, NPI 1629356803, CMS profile ID 1391149. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1629356803?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SARAH ANN WEISS, NPI 1629356803, CMS profile ID 1391149, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1629356803?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $539.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $269.8601/02/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101241856 CMS
E.R. Squibb & Sons, L.L.C. $269.8601/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101241906 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2022 $103.67 1
PY2023 $9,431.67 12
PY2024 $539.72 2
PY2025 $20,357.80 17

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $597.30 2
PY2025 Principal investigator $514,882.78 49
PY2024 Principal investigator $78,800.00 1
PY2023 Principal investigator $151,569.00 62
PY2022 Principal investigator $143,169.53 9
PY2021 Principal investigator $143,050.61 6
PY2020 Principal investigator $311,362.59 23
PY2019 Principal investigator $106,482.80 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.03 11/25/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184264371
Principal investigator 1 Immunocore Limited $2,467.40 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146867
Principal investigator 1 Immunocore Limited $1,807.00 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146869
Principal investigator 1 Immunocore Limited $1,807.00 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146871
Principal investigator 1 Immunocore Limited $2,095.60 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146873
Principal investigator 1 Immunocore Limited $2,570.92 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146875
Principal investigator 1 Immunocore Limited $4,494.75 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146877
Principal investigator 1 Immunocore Limited $3,272.75 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146879
Principal investigator 1 Immunocore Limited $4,161.61 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146881
Principal investigator 1 Immunocore Limited $3,251.30 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146883
Principal investigator 1 Immunocore Limited $3,251.30 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146885
Principal investigator 1 Immunocore Limited $1,955.59 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146887
Principal investigator 1 Immunocore Limited $1,955.59 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146889
Principal investigator 1 Immunocore Limited $1,955.59 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146891
Principal investigator 1 Immunocore Limited $3,251.30 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146893
Principal investigator 1 Immunocore Limited $3,251.30 11/19/2025 Non-covered Recipient Entity
Rutgers, the State University
Randomized Phase 2/3 Study of Tebentafusp Monotherapy or with Pembrolizumab Versus Chemotherapy in HLA-A*02:01-positive Patients with Previously Treated Metastatic Cutaneous Melanoma (TEBE-CM) No dispute reported 06/30/2026 1212146895
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,494.17 11/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184261003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,596.22 11/07/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184257951
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.03 10/09/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184249116
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $748.60 09/18/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184240430
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $547.20 09/18/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184240752
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,596.22 09/18/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184240754
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,408.76 09/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184236770
Principal investigator 1 Merck Sharp & Dohme LLC $316,800.00 09/05/2025 Non-covered Recipient Entity
Rutgers Cancer Center
An Open-Label Phase 1a,1b Dose-Escalation and Expansion Study Investigating the Safety, Pharmacokinetics, Pharmacodynamics, and Activity of AB248 Alone or in Combination with Pembrolizumab in Adult Patients With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1232932641
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.03 09/04/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184235337
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $899.60 08/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,682.60 08/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,673.74 08/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184228459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,384.04 07/22/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217965
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,260.20 07/17/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184217288
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $547.20 07/10/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184214564
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,596.22 06/24/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184210786
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.03 06/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184206573
Recipient Regeneron Pharmaceuticals, Inc. $351.65 06/01/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123886
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,508.00 05/27/2025 Non-covered Recipient Entity
Cancer Institute Of New Jersey
A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy with Nivolumab versus Ipilimumab after Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects who are at High Risk for Recurrence No dispute reported 06/30/2026 1235998420
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,086.50 05/22/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,582.20 05/22/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197739
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,596.22 05/22/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184197741
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,006.15 05/15/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184194943
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,766.03 04/28/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184190709
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,362.25 04/15/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184183364
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $29,050.00 04/01/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184180712
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,599.00 04/01/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184180714
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,208.00 04/01/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184180716
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,250.00 04/01/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184180718
Recipient Regeneron Pharmaceuticals, Inc. $245.65 03/25/2025 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND PHASE 2/3 STUDY OF FIANLIMAB (ANTI-LAG-3 ANTIBODY) IN COMBINATION WITH CEMIPLIMAB (ANTI-PD-1 ANTIBODY) VERSUS CEMIPLIMAB MONOTHERAPY IN FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH TUMORS EXPRESSING PD-L1 =50% No dispute reported 06/30/2026 1184123884
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,362.25 03/12/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184170930
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,033.00 02/25/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184155532
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,572.34 01/29/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA No dispute reported 06/30/2026 1184149998
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,019.95 01/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184147521
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,033.00 01/14/2025 Non-covered Recipient Entity
RUTGERS THE STATE UNIVERSITY OF NEW JERSEY
A Phase 2 and Phase 3 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma No dispute reported 06/30/2026 1184147523